Cover Image
市場調查報告書

Yuhan Corporation : 產品平台分析

Yuhan Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251735
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
Yuhan Corporation : 產品平台分析 Yuhan Corporation - Product Pipeline Review - 2016
出版日期: 2016年05月25日 內容資訊: 英文 54 Pages
簡介

Yuhan Corporation 是進行醫藥品的研究開及製造,在國內外發展的製藥公司。該公司不僅提供API(醫藥品有效成分),更有冠狀動脈疾病、高血壓、脂質異常、腦血栓症和其他疾病的治療藥。

本報告提供Yuhan Corporation 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Yuhan Corporation的基本資料

  • Yuhan Corporation的概要
  • 主要資訊
  • 企業資料

Yuhan Corporation :R&D概要

  • 主要的治療範圍

Yuhan Corporation :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Yuhan Corporation :開發中產品概況

  • 最後階段的開發中產品
    • 第Ⅲ期的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第Ⅱ期的產品/聯合治療模式
    • 第Ⅰ期的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Yuhan Corporation :藥物簡介

Yuhan Corporation :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Yuhan Corporation :最近的開發平台趨勢

Yuhan Corporation :暫停中的計劃

Yuhan Corporation :企業發表

Yuhan Corporation :總公司和子公司的所在地

Yuhan Corporation :主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08056CDB

Summary

Global Markets Direct's, 'Yuhan Corporation - Product Pipeline Review - 2016', provides an overview of the Yuhan Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Yuhan Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Yuhan Corporation
  • The report provides overview of Yuhan Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Yuhan Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Yuhan Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Yuhan Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Yuhan Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Yuhan Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Yuhan Corporation Snapshot
    • Yuhan Corporation Overview
    • Key Information
    • Key Facts
  • Yuhan Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Yuhan Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Yuhan Corporation - Pipeline Products Glance
    • Yuhan Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Yuhan Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Yuhan Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Yuhan Corporation - Drug Profiles
    • (metformin hydrochloride SR + rosuvastatin calcium)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bilastine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-12852
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-14618
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (amlodipine maleate + chlorthalidone + telmisartan)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-22189
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-1177
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-14619
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-18406
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-18420
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-24931
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-25348
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-25448
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-25723
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-BIO
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-GKA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-NCE2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-NCE3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-NCE4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-siRNA1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-siRNA2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YH-siRNA3
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Yuhan Corporation - Pipeline Analysis
    • Yuhan Corporation - Pipeline Products by Target
    • Yuhan Corporation - Pipeline Products by Route of Administration
    • Yuhan Corporation - Pipeline Products by Molecule Type
    • Yuhan Corporation - Pipeline Products by Mechanism of Action
  • Yuhan Corporation - Recent Pipeline Updates
  • Yuhan Corporation - Dormant Projects
  • Yuhan Corporation - Company Statement
  • Yuhan Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Yuhan Corporation - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Yuhan Corporation, Key Information
  • Yuhan Corporation, Key Facts
  • Yuhan Corporation - Pipeline by Indication, 2016
  • Yuhan Corporation - Pipeline by Stage of Development, 2016
  • Yuhan Corporation - Monotherapy Products in Pipeline, 2016
  • Yuhan Corporation - Combination Treatment Modalities in Pipeline, 2016
  • Yuhan Corporation - Partnered Products in Pipeline, 2016
  • Yuhan Corporation - Partnered Products/ Combination Treatment Modalities, 2016
  • Yuhan Corporation - Phase III, 2016
  • Yuhan Corporation - Phase II, 2016
  • Yuhan Corporation - Phase I, 2016
  • Yuhan Corporation - Preclinical, 2016
  • Yuhan Corporation - Pipeline by Target, 2016
  • Yuhan Corporation - Pipeline by Route of Administration, 2016
  • Yuhan Corporation - Pipeline by Molecule Type, 2016
  • Yuhan Corporation - Pipeline Products by Mechanism of Action, 2016
  • Yuhan Corporation - Recent Pipeline Updates, 2016
  • Yuhan Corporation - Dormant Developmental Projects,2016
  • Yuhan Corporation, Other Locations
  • Yuhan Corporation, Subsidiaries
  • Yuhan Corporation, Key Manufacturing Facilities

List of Figures

  • Yuhan Corporation - Pipeline by Top 10 Indication, 2016
  • Yuhan Corporation - Pipeline by Stage of Development, 2016
  • Yuhan Corporation - Monotherapy Products in Pipeline, 2016
  • Yuhan Corporation - Combination Treatment Modalities in Pipeline, 2016
  • Yuhan Corporation - Partnered Products in Pipeline, 2016
  • Yuhan Corporation - Pipeline by Top 10 Target, 2016
  • Yuhan Corporation - Pipeline by Route of Administration, 2016
  • Yuhan Corporation - Pipeline by Molecule Type, 2016
  • Yuhan Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top